Analytics, Innovation & Research, College of Physicians and Surgeons, Edmonton, Alberta, Canada
Analytics, Innovation & Research, College of Physicians and Surgeons, Edmonton, Alberta, Canada.
BMJ Open. 2023 Oct 19;13(10):e070066. doi: 10.1136/bmjopen-2022-070066.
To determine if inappropriate tapering/discontinuation of opioids to Alberta patients occurred from mid-2013-2020, as unintended consequences of prescribing guidelines, regulations and policies in response to the North American opioid crisis.
A population-based, repeated cross-sectional time-series study.
Alberta, Canada.
Residents of Alberta, Canada aged 18 and older who received an opioid dispense from a community pharmacy from 2013 to 2020.
The prevalence of potential rapid tapering was measured at a given date (reference day), enveloped by a data window. Dose changes were measured as oral morphine equivalents (OME) per patient, at multiple time points ('data window' around a reference day). Chronic recipients were identified, and their prescriptions were contrasted 90 days before and after the reference day to measure OME/day changes.
Approximately 9000 dispenses (totalling ~6 million OME) per day were analysed from 2013 to 2020. The total number of opioid recipients was highly cyclic in nature (peaking in winter). The number of chronic opioid recipients remained somewhat stable from ~70K in 2013 to ~86K at the end of 2020. The number of chronic high and very high dose recipients presented a significant decrease after 2017. Approximately 11%-12% of chronic high-dose recipients experienced potential rapid dose tapering at a rate of 50% or more prereference to postreference day at any given point of time. For chronic very high dose recipients, approximately 11.5% experience potential rapid dose tapering at a rate of 50% or more prereference to postreference day at any given point of time. Potential discontinuation remained constant and the interventions did not have a significant impact on the trend.
The evidence suggests that changes in prescribing guidelines were not associated with an increase of rapid opioid tapering/discontinuation in Alberta.
确定 2013 年至 2020 年间,由于应对北美阿片类药物危机的处方指南、法规和政策的意外后果,艾伯塔省患者的阿片类药物是否不合理地逐渐减少/停止。
一项基于人群的、重复的横断面时间序列研究。
加拿大艾伯塔省。
2013 年至 2020 年期间从社区药房获得阿片类药物处方的艾伯塔省 18 岁及以上的居民。
在给定日期(参考日)及其数据窗口内,测量潜在快速减少的流行率。剂量变化以每个患者的口服吗啡当量(OME)来衡量,在多个时间点(参考日周围的“数据窗口”)。确定慢性接受者,并在参考日前后 90 天对比他们的处方,以测量 OME/天的变化。
2013 年至 2020 年期间,每天约有 9000 次配药(总计约 600 万 OME)进行了分析。阿片类药物接受者的总数具有高度周期性(冬季达到高峰)。慢性阿片类药物接受者的数量从 2013 年的约 70K 到 2020 年底的约 86K 保持相对稳定。2017 年后,慢性高剂量和极高剂量接受者的数量明显减少。在任何给定时间点,约 11%-12%的慢性高剂量接受者在参考日前后以 50%或更高的速度经历潜在的快速剂量减少。对于慢性极高剂量接受者,约 11.5%在任何给定时间点以 50%或更高的速度经历潜在的快速剂量减少。潜在的停药率保持不变,干预措施对趋势没有显著影响。
证据表明,处方指南的变化与艾伯塔省阿片类药物快速减少/停止的增加无关。